70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers

Abstract Association of estrogen receptor (ER), progesterone receptor (PR), HER2, Ki67 and 70-gene classifier (70-GC) with a response to paclitaxel (PAC) ( n = 79) or docetaxel (DOC) ( n = 55) was investigated in the neoadjuvant setting for breast cancer patients. Sensitivity of breast tumors to PAC...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2012-01, Vol.314 (2), p.206-212
Main Authors: Naoi, Y, Tanei, T, Kishi, K, Tsunashima, R, Tominaga, N, Baba, Y, Nakayama, T, Shimazu, K, Kim, S.J, Tamaki, Y, Noguchi, S
Format: Article
Language:English
Subjects:
70-Gene classifier
analysis
Antineoplastic Agents, Phytogenic
Antineoplastic Agents, Phytogenic - therapeutic use
Breast cancer
breast neoplasms
Breast Neoplasms - classification
Breast Neoplasms - drug therapy
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Cancer therapies
Cell cycle
Chemotherapy
classification
Deoxyribonucleic acid
DNA
DNA microarray
Docetaxel
drug therapy
estrogen receptors
Female
Gene expression
Gene Expression Profiling
genetics
Hematology, Oncology and Palliative Medicine
Humans
Ki-67 Antigen
Ki-67 Antigen - analysis
Paclitaxel
Paclitaxel - therapeutic use
pathology
Patients
progesterone receptors
Receptor, ErbB-2
Receptor, ErbB-2 - analysis
Receptors, Estrogen
Receptors, Estrogen - analysis
Receptors, Progesterone
Receptors, Progesterone - analysis
Response rates
Taxoids
Taxoids - therapeutic use
therapeutic use
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Association of estrogen receptor (ER), progesterone receptor (PR), HER2, Ki67 and 70-gene classifier (70-GC) with a response to paclitaxel (PAC) ( n = 79) or docetaxel (DOC) ( n = 55) was investigated in the neoadjuvant setting for breast cancer patients. Sensitivity of breast tumors to PAC, but not to DOC, was found to be significantly associated with ER negativity ( P = 0.003), PR negativity ( P = 0.007), and Ki67 positivity ( P = 0.007). Breast tumors classified into the responders by 70-GC showed a significantly ( P = 0.005) higher reduction rate to PAC and interestingly a significantly ( P = 0.009) lower reduction rate to DOC than those classified into the non-responders by 70-GC, suggesting that 70-GC might be useful for the differentiation of PAC-sensitive and DOC-sensitive breast tumors.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2011.09.032